Ianchulev Tsontcho, Lane Stephen, Masis Marisse, Lass Jonathan H, Benetz Beth Ann, Menegay Harry J, Price Francis W, Lin Shan
New York Eye and Ear Infirmary of Mount Sinai, New York, NY.
Alcon, Fort Worth, TX.
Cornea. 2019 Mar;38(3):325-331. doi: 10.1097/ICO.0000000000001826.
To evaluate corneal endothelial cell density (ECD) and morphology 2 years after phacoemulsification in subjects from the COMPASS trial (ClinicalTrials.gov, NCT01085357) who had mild-to-moderate primary open-angle glaucoma and visually significant cataracts.
The central corneal endothelium was evaluated by serial specular microscopy at 0 to 24 months. ECD, coefficient of variation, and percentage of hexagonal cells were evaluated by a central image analysis reading center and central corneal thickness (CCT) was evaluated by ultrasound pachymetry.
Of 131 subjects who underwent routine phacoemulsification, analyzable endothelial images at 24 months were available for 126 subjects (96.2%). Mean ± SD central ECD at baseline was 2453 ± 359 cells/mm, decreasing by 10% ± 14% to 2195 ± 517 cells/mm at 3 months (P < 0.001) but stabilizing thereafter with mean endothelial cell loss (ECL) from baseline to 24 months of 9% ± 13% (P < 0.001). Twelve (9.5%) and 10 (7.9%) subjects experienced >30% ECL at 12 and 24 months, respectively. Neither coefficient of variation nor percentage of hexagonal cells changed significantly from baseline at any time point. Mean CCT was similar at baseline (550 ± 35 μm) and at 12 months (551 ± 37 μm) and 24 months (555 ± 35 μm). Age was significantly associated with ECL after cataract surgery (P = 0.02), but baseline intraocular pressure, number of glaucoma medications, and CCT were not. Similar results were observed in patients who underwent CyPass micro-stent implantation accompanying phacoemulsification.
Phacoemulsification in eyes with mild-to-moderate primary open-angle glaucoma results in early ECL, with ECD stabilizing after 3 months and no effect on other endothelial stress markers up to 2 years postoperatively.
在COMPASS试验(ClinicalTrials.gov,NCT01085357)中患有轻度至中度原发性开角型青光眼和具有明显视觉影响的白内障的受试者中,评估白内障超声乳化术后2年的角膜内皮细胞密度(ECD)和形态。
通过连续镜面显微镜在0至24个月评估中央角膜内皮。由中央图像分析读取中心评估ECD、变异系数和六边形细胞百分比,并通过超声测厚法评估中央角膜厚度(CCT)。
在131例行常规白内障超声乳化术的受试者中,126例(96.2%)在24个月时有可分析的内皮图像。基线时中央ECD的平均值±标准差为2453±359个细胞/mm²,在3个月时下降10%±14%至2195±517个细胞/mm²(P<0.001),但此后稳定,从基线到24个月的平均内皮细胞丢失(ECL)为9%±13%(P<0.001)。分别有12例(9.5%)和10例(7.9%)受试者在12个月和24个月时ECL>30%。在任何时间点,变异系数和六边形细胞百分比与基线相比均无显著变化。基线时平均CCT为(550±35μm),12个月时为(551±37μm),24个月时为(555±35μm),三者相似。年龄与白内障手术后的ECL显著相关(P=0.02),但基线眼压、青光眼药物使用数量和CCT则不然。在白内障超声乳化术同时行CyPass微支架植入的患者中观察到类似结果。
轻度至中度原发性开角型青光眼患者行白内障超声乳化术后会出现早期ECL,ECD在3个月后稳定,术后2年内对其他内皮应激标志物无影响。